RxDoctor Payments Data

Howard Kroop, MD

Gastroenterology · Phila, PANPI 1427027614

Payments from drug & device makers

$4,258in general payments, 2019–2025

Across 295 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$579
  • Bristol Myers Squibb$365
  • Takeda Pharmaceuticals U.S.A., Inc.$252
  • Gilead$240
  • Johnson & Johnson$197
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,258100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,258 in reported general payments places this provider in the 60th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$165,692
Medicare patients
588
Services billed
2,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$87,482
RinvoqUpadacitinib12$79,104
Humira(Cf)Adalimumab12$73,585
LinzessLinaclotide70$70,722
XifaxanRifaximin15$33,613
ZenpepLipase/Protease/Amylase21$32,225
CreonLipase/Protease/Amylase16$25,104
Mesalamine35$21,686
Dexlansoprazole DrDexlansoprazole42$13,550
Ursodiol36$8,849
Pantoprazole Sodium278$4,646
Sucralfate48$4,503
Omeprazole293$3,751
Budesonide EcBudesonide42$3,585
Colestipol Hcl35$2,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Linzess, Creon$1,574$248,515110 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$579$33,61315 claims
Aimmune Therapeutics, Inc.Zenpep$118$32,22521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →